Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.
According to Novo Nordisk's latest financial reports the company's current earnings are โน47.21 Billion. In 2024 the company made an earning of โน1.700 Trillion, an increase over its 2023 earnings that were of โน1.384 Trillion. The earnings displayed on this page is the company's Pretax Income.